BMS Advances Cardiovascular Growth Plans With Milvexian, Camzyos Milestones
Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.
You may also be interested in...
J.P. Morgan Day One: Biopharma Braces For Headwinds Ahead
Daily notebook from the J.P. Morgan Healthcare Conference: Turbulent weather matches sentiment about the year ahead, with investors looking for reassurance on the IRA, deal-making and growth strategy from big pharma. Updates from J&J, Biogen, BMS, Merck and more.
Confidence In Factor XIa Inhibition Wavers After Bristol/Janssen And Bayer Data
BMS/Janssen’s milvexian and Bayer’s asundexian prevented strokes without major increases in severe bleeding and no fatal bleeds but Phase III outcomes are uncertain based on mixed Phase II data.
Bayer Outlines Asundexian Phase III Plan, Hoping To Prove Safety Benefit Over Eliquis
The Factor XIa inhibitor could be an effective anticoagulant without the increased risk in bleeding associated with current Factor Xa inhibitors, but the profile will need to be confirmed in Phase III.